Subscriber Action Required: ExpreS2ion Press Release Distribution Moves to MFN
20 januari, 14:00
Subscriber Action Required: ExpreS2ion Press Release Distribution Moves to MFN
Hørsholm, Denmark, 20 January 2026 – ExpreS2ion Biotech Holding AB’s today announces that, effective today, 20 January 2026, the Company will transition its press release distribution from Cision to MFN (Modular Finance News). Subscribers who wish to continue receiving the Company’s press releases must register on the MFN platform. This change is part of the Company’s ongoing efforts to streamline regulatory news distribution.
To continue receiving Expres2ion Biotech Holding’s press releases, including future regulatory announcements, current subscribers of Cision News are required to register on the MFN platform.
How to subscribe via MFN
Subscribers can sign up to receive future press releases and updates here:
https://mfn.se/all/a/expres2ion-biotech-holding
Once registered, subscribers will receive press releases and other Company announcements directly through MFN’s distribution channels.
About the Change
The Company has selected MFN as its official distribution service for press releases and regulatory announcements, providing reliable and compliant dissemination to the market.
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
About ExpreS2ion
ExpreS2ion is a biotechnology company that develops innovative vaccines for a healthier world. We want to transform healthcare by developing novel vaccines, that are life-saving and improving quality of life across the world. ExpreS2ion has developed the unique human clinical Phase III-validated technology platform, ExpreS2™, for fast and efficient development and production of the active material in vaccines. The platform, under the brand GlycoX-S2™, includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, ExpreS2ion has produced more than 500 proteins and virus-like particles (VLPs) in collaboration with leading research institutions and companies. ExpreS2ion develops novel VLP based vaccines in association with AdaptVac ApS, of which ExpreS2ion owns 34%. For additional information, please visit www.expres2ionbio.com.
For further information about ExpreS2ion Biotech Holding AB, please contact:
Bent U. Frandsen, CEO
Keith Alexander, CFO
E-mail: investor@expres2ionbio.com
Ämnen i artikeln
Subscriber Action Required: ExpreS2ion Press Release Distribution Moves to MFN
20 januari, 14:00
Subscriber Action Required: ExpreS2ion Press Release Distribution Moves to MFN
Hørsholm, Denmark, 20 January 2026 – ExpreS2ion Biotech Holding AB’s today announces that, effective today, 20 January 2026, the Company will transition its press release distribution from Cision to MFN (Modular Finance News). Subscribers who wish to continue receiving the Company’s press releases must register on the MFN platform. This change is part of the Company’s ongoing efforts to streamline regulatory news distribution.
To continue receiving Expres2ion Biotech Holding’s press releases, including future regulatory announcements, current subscribers of Cision News are required to register on the MFN platform.
How to subscribe via MFN
Subscribers can sign up to receive future press releases and updates here:
https://mfn.se/all/a/expres2ion-biotech-holding
Once registered, subscribers will receive press releases and other Company announcements directly through MFN’s distribution channels.
About the Change
The Company has selected MFN as its official distribution service for press releases and regulatory announcements, providing reliable and compliant dissemination to the market.
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
About ExpreS2ion
ExpreS2ion is a biotechnology company that develops innovative vaccines for a healthier world. We want to transform healthcare by developing novel vaccines, that are life-saving and improving quality of life across the world. ExpreS2ion has developed the unique human clinical Phase III-validated technology platform, ExpreS2™, for fast and efficient development and production of the active material in vaccines. The platform, under the brand GlycoX-S2™, includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, ExpreS2ion has produced more than 500 proteins and virus-like particles (VLPs) in collaboration with leading research institutions and companies. ExpreS2ion develops novel VLP based vaccines in association with AdaptVac ApS, of which ExpreS2ion owns 34%. For additional information, please visit www.expres2ionbio.com.
For further information about ExpreS2ion Biotech Holding AB, please contact:
Bent U. Frandsen, CEO
Keith Alexander, CFO
E-mail: investor@expres2ionbio.com
Ämnen i artikeln
Aktier
Analyser
Förvaltarbyten
Inflationen
Bostadspriser
Aktier
Analyser
Förvaltarbyten
Inflationen
Bostadspriser
Marknadsöversikt
1 DAG %
Senast
1 mån
